Context: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease. Hypophosphatemia was demonstrated in adult patients with preserved renal function, together with high fibroblast growth factor 23 (FGF23) and low soluble Klotho levels. The latter explained the relative FGF23 hyporesponsiveness in this cohort.
were not different from controls, they should be considered inappropriate, given the concomitant hypophosphatemia. Further studies are required to elucidate underlying pathophysiology and potential clinical consequences. (J Clin Endocrinol Metab 102: [4210] [4211] [4212] [4213] [4214] [4215] [4216] [4217] 2017) A utosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, arising as a consequence of mutations in the PKD1 or PKD2 genes (1) . These genes encode the proteins polycystin-1 (PC1) and polycystin-2, respectively, essential for renal tubular morphogenesis, mechanosensing, intracellular signaling pathways, and function of the primary cilium (2) . Recently, mutations in GANAB, encoding glucosidase II subunit a, were shown to cause ADPKD as well, most likely via defects in PC1 maturation (3) . Apart from the well-known progressive renal phenotype, ADPKD is a multisystemic disorder. Extrarenal manifestations include polycystic liver disease, cardiovascular disease, cerebral aneurysm, colonic diverticula, and male infertility (4) . Mounting evidence points to a link between ADPKD and mineral and bone disease as well.
In an adult ADPKD cohort with chronic kidney disease (CKD) stage 1-2, elevated levels of fibroblast growth factor 23 (FGF23), a phosphaturic hormone produced by osteocytes, have been reported (5) . Hypophosphatemia and renal phosphate wasting were observed in 38% and 13% of these patients, respectively (5) . It remains a matter of ongoing controversy whether FGF23 produced by polycystic kidneys contributes to the renal phosphate leak. Remarkably, the tubular maximum phosphorus reabsorption per glomerular filtration rate (TmP/GFR) was higher than would be expected from the FGF23 exposure. This suggests that adult ADPKD is a state of FGF23 hyporesponsiveness (6) . Additional studies revealed Klotho deficiency as the most plausible culprit of this peripheral resistance to FGF23.
Moreover, preliminary experimental evidence suggests that bone metabolism is disturbed in ADPKD (7, 8) . First, PC1, polycystin-2, and primary cilia were shown to be expressed in murine osteoblast and osteocyte cell lines (9) . PC1 regulates osteoblast differentiation and adipogenesis through intracellular Ca 2+ -dependent stimulation of Runx2-II expression, a bone-specific transcription factor (10) . In vivo studies in mice confirmed these in vitro data, showing that an inactivating Pkd1 missense mutation led to delayed bone formation, indicating the requirement of PC1 for normal chondrocyte differentiation and maturation (9) . In line with these experimental data, a few case reports describe bone impairment in ADPKD patients (11) (12) (13) (14) . Also, remarkably, some syndromes are characterized by both skeletal defects and polycystic kidneys; these include oral-facial-digital syndrome type 1 and serpentine fibula-polycystic kidney syndrome (7) .
Excited by these findings, we questioned whether mineral or bone abnormalities are already present in early disease stage. To test this hypothesis, we investigated phosphate and bone metabolism in a large cohort of children diagnosed with ADPKD.
Subjects and Methods

Study participants and procedures
The study was conducted as a multicenter cross-sectional cohort study. ADPKD patients were enrolled from five Belgian tertiary pediatric nephrology departments. Inclusion criteria were: diagnosis of ADPKD, age ,19 years, and estimated glomerular filtration rate (eGFR) $60 mL/min/1.73 m 2 (CKD stage 1-2) to minimalize the effect of renal dysfunction on bone metabolism. ADPKD diagnosis was defined as the presence of a single renal cyst on ultrasound in a child from a known ADPKD family (15) and/or a genetic analysis because the latter was not systematically used or available in all centers. The eGFR was calculated using the Schwartz 2009 equation (16) and full age spectrum formula based on height or age (17) . Hyperfiltration was defined as an eGFR $150 mL/min/1.73 m 2 (18) . Healthy controls (HCs) aged ,19 years were recruited as the control group. Anthropometric data including age, sex, body weight, height, body mass index, expressed as standard deviation (SD) scores, blood pressure, and puberty state according to Tanner (19) ; details of medical personal/familial history and drug intake were collected at enrollment from all patients. Prepuberty was defined as Tanner stage 1; puberty as stage 2 to 4 and postpuberty as stage 5 (19) ; analyses were performed in prepuberty vs postpuberty children. Children were small for age when height SD score was ,2 and they had a low body mass index when the SD score was ,2. A specific questionnaire on bone health, including previous fractures or bone deformities, was performed. Nephromegaly was assessed by ultrasound and was defined if renal length was $2 SDs above normal for sex and height (20) .
The study was conducted according to the Declaration of Helsinki and the guidelines of Good Clinical Practice. Study approval was obtained from the local ethics committees, and all patients, HC, and their parents gave written, informed consent.
Biological data and analytical methods
Blood and spot urine samples were collected from all participants. These were analyzed for the following validated routine levels: creatinine, sodium, potassium, calcium, phosphate, uric acid, urea nitrogen, osmolality, and glucose in both serum and urine; total protein and alpha-1-microglobulin in urine; and bicarbonate and albumin in serum. The remaining plasma, serum, and urine aliquots were centrifuged and stored at 280°C within 4 hours after collection to prevent sample stability problems (6 (21, 22) and has the following characteristics: detection limit, 0.08 pmol/L; lower limit of quantification, 0.1 pmol/L; interassay precision, ,10%; and accuracy, 96% to 101%. TmP/GFR, in mmol/L, was calculated according to the formula of Brodehl (23) . TmP/GFR values were considered low, normal, or high for age according to the reference values determined by Payne (24) . Because serum phosphate concentrations vary with age in children, we expressed the phosphate value for each participant as an SD score relative to age-matched values from healthy children representing the normal population (25) . Blood sampling was performed after fasting and before noon, unless impossible because of the young age. Blood sampling conditions were recorded per subject. For TmP/GFR and serum phosphate levels, percentile charts were made based on the reference values (24, 25) . Low TmP/GFR was defined as values below the lower limit of normal for age (24, 25) . Ratios of urinary protein-to-creatinine ratio $0.2 g/g in children older than 2 years of age or $0.5 g/g in infants and toddlers until 24 months of age were defined as proteinuria (26) . 
Statistical analysis
All statistical analyses were performed using IBM SPSS 17.0 software for Windows. Multiple comparisons were performed using the Kruskal-Wallis test; comparisons between groups were performed using the Mann-Whitney U test. Bivariate correlations were computed with the Spearman test. Linear regression analysis was used to determine independent associations between phosphatemia and the following variables: age, GFR, TmP/GFR, BAP, PTH, and sclerostin. All significant tests were performed at the two-sided 0.05 level of significance. Data are presented as mean 6 SD or as median (minimum, maximum) if not normally distributed.
Results
Participant characteristics
Ninety-two ADPKD patients and 22 HC were included at a mean age 6 SD of 10.2 6 5.0 and 10.3 6 4.1 years, respectively (Table 1) . Of the 92 children in the ADPKD cohort, 54 had a PKD1 mutation and 1 was confirmed to have a PKD2 mutation.
There were no differences in anthropometric data between ADPKD and HC cohorts. The eGFR was .90 mL/min/1.73 m 2 (CKD1) in 81 (88%) ADPKD patients and between 60 and 90 mL/min/1.73 m 2 (CKD2) in 11 (12%) ADPKD patients. Similar results were obtained when applying the full age spectrum formula in both HC and ADPKD patients (data not shown). No substantial differences between both groups in vitamin D supplement use, bone fractures, or skeletal deformities in the personal history were noted. Two (9%) HC had a bone fracture in the past compared with 13 (14%) ADPKD patients, of which one patient had multiple fractures: six fractures, of which three were low-impact fractures, between the ages of 5 to 11 years. Three (3%) ADPKD patients presented a skeletal anomaly, namely one with pectus excavatum, one with a large cystic bone structure in the third mandibular quadrant and one with a structurally abnormal foot posture.
Phosphate metabolism
ADPKD patients had significantly lower phosphate SD scores compared with HC (P = 0.02) ( Fig. 1a; Table 2 ). Although 24% of ADPKD patients had low TmP/GFR values compared with 9% of HC (P = 0.21), the absolute frequency distribution per 0.1 mmol/L interval of TmP/ GFR for both groups revealed a prevalence of low TmP/ GFR values in ADPKD patients compared with HC (Fig. 1b) .
Patients had low normal values for both serum phosphate and TmP/GFR according to age-corrected percentile curves (Fig. 1c-1d) . The number of patients with phosphatemia levels below percentile 5, between 5 and 50, between 50 and 95, and above 95 were: 8 (9%), 70 (76%), 14 (15%), and 0 (0%), respectively. TmP/GFR percentile distribution was: 22 (24%), 66 (73%), 2 (2%), and 0 (0%), respectively. Although phosphate SD score was not influenced by puberty stage, 11 prepuberty ADPKD patients had low TmP/GFR values vs 49 in the postpuberty subgroup (P , 0.001).
Serum phosphate SD score levels significantly correlated with TmP/GFR in ADPKD patients (r 2 = 0.69, P , 0.0001) and HC (r 2 = 0.75, P , 0.0001) (Fig. 1e ).
ADPKD patients with normal TmP/GFR values had significantly higher levels of serum phosphate SD scores compared with ADPKD patients with a low TmP/GFR (P , 0.0001, Fig. 1f ). Both FGF23 and sKlotho levels were similar between the ADPKD and HC cohorts (Table 2) . Moreover, these levels were similar between the low vs normal TmP/GFR patients (P = 0.82 and P = 0.39, respectively), CKD1 vs CKD2 patients (P = 0.83 and P = 0.17, respectively), patients with or without nephromegaly (P = 0.44 and P = 0.69, respectively), and pre-vs postpuberty ADPKD (P = 0.53 and P = 0.93, respectively). No clear trend was seen in the change in FGF23 or serum phosphate SD score based on eGFR in the ADPKD cohort (Supplemental Fig. 1) . Evaluation of the proximal tubular function, including serum and/or urinary bicarbonate, sodium, glucose, potassium, glucose, calcium, and alpha 1 microglobulin levels, was within the normal range (data not shown).
The serum levels of other hormones known to regulate phosphate homeostasis were measured to elucidate their effect on the difference in serum phosphate and TmP/ GFR (Table 2 ). Comparing the ADPKD and HC groups, no important differences were found for 25(OH)D, 1,25(OH) 2 D, or PTH levels. None of HC and 6% of ADPKD patients had severe vitamin D deficiency and 36% of HC and 21% of ADPKD patients had vitamin D deficiency. For the ADPKD patients, the results were not different when comparing the patients with a confirmed genetic diagnosis vs those without (data not shown). Moreover, subgroup analysis from all included subjects for serum phosphate SD score in fasting vs nonfasting children and for diurnal variation in blood sampling showed no differences (data not shown).
Bone metabolism
Compared with HC, ADPKD patients displayed significantly lower values of BAP (P = 0.01). Sclerostin however, did not significantly differ between the two groups (P = 0.23; Table 2 ). Strikingly, bivariate analysis showed a significant relation between both serum phosphate, serum phosphate SD score, TmP/GFR on the one hand, and BAP and sclerostin on the other hand, in the ADPKD cohort (Table 3) .
Discussion
The main finding of this study is that abnormalities of phosphate and bone metabolism already occur in earlystage ADPKD. Pediatric patients show lower serum phosphate levels and lower BAP levels compared with HC.
The observation of a disturbed phosphate metabolism in ADPKD patients with a preserved renal function extends data previously reported in adult ADPKD patients (5); however, the "phenotype" of the phosphate metabolism disturbance shows marked differences (5, 8, 28) . Although FGF23 levels were clearly increased in adult patients, these levels remained within the normal range in ADPKD children. How to explain these apparent discrepancies?
Although a different FGF23 assay was used in the adult study compared with ours, given the high correlations between both assays, the differences regarding FGF23 levels in ADPKD childhood vs adulthood cannot be explained by methodological deviations (21, 22) .
Both a higher skeletal and extraskeletal FGF23 production and FGF23 resistance may be hypothesized to contribute to the increased FGF23 levels in ADPKD adults. First, although debated, recent evidence suggests extraosseous FGF23 production by renal cyst lining cells to contribute to the increased circulating FGF23 levels (8) . Second, a peripheral FGF23 resistance or hyporesponsiveness has been observed in adult ADPKD patients across different CKD stages (8, 28) . This hyporesponsiveness appears to be related to sKlotho deficiency (8) , which, in the SUISSE cohort, was shown to be correlated with the total kidney volume, an important marker for disease progression (6) . Assuming circulating sKlotho is a valid biomarker of renal Klotho expression (29) , our pediatric cohort should be considered Klotho sufficient, given the comparable sKlotho levels in patients and HCs, and thus fully responsive to FGF23. Moreover, because their renal cyst burden is less compared with adult patients, their presumed extraosseous FGF23 production should be lower. These mechanisms may explain why our pediatric patients showed FGF23 concentrations within the normal range, as opposed to what has been demonstrated in adult ADPKD. Nevertheless, given the concomitant hypophosphatemia, normal FGF23 levels in the pediatric cohort should be labeled as "inappropriately normal." Importantly, we also excluded the involvement of vitamin D, PTH, and nonspecific proximal tubular dysfunction. In addition, we observed low levels of BAP in ADPKD children. This finding raises the hypothesis of suppressed bone formation in ADPKD and is in line with data from a small bone biopsy study that showed a preponderance of low bone turnover disease in young adult ADPKD patients with preserved kidney function (30) . PTH, the major driver of bone remodeling, is unlikely to be involved because serum levels were only marginally lower in ADPKD patients compared with controls. Another culprit might be sclerostin, a circulating inhibitor of the osteo-anabolic Wnt/b-catenin signaling pathway. In general, sclerostin levels are increased in adults with early CKD (31) . A growing body of evidence suggests that ADPKD might be considered a state of sclerostin excess, potentially related to dysfunctional mechanosensation in osteocytes (32) . Higher osseous sclerostin expression has been reported in the jck mouse, a genetic model of polycystic kidney disease with a phenotype including cardiovascular abnormalities and skeletal changes as typically seen in CKD-mineral bone disease (33) . Very recently, increased sclerostin levels in combination with low total alkaline phosphatase concentrations have been observed in a large adult ADPKD patient cohort with end-stage renal disease, compared with patients with other primary renal disease (34) . In the current study, sclerostin levels in ADPKD children did not differ from HC. Case mix, puberty stage, power issues, and assay issues may explain these apparently contradictory findings. Moreover, data on circulating sclerostin levels in pediatric healthy and CKD populations are limited and not unequivocal (e.g. with regard to the impact of puberty stage, sex, and hyperparathyroidism) (35, 36) .
As opposed to what is observed in their adult counterparts, pediatric CKD patients moreover showed decreased circulating sclerostin levels in various cohort studies (31, 37) . This discrepancy remains to be elucidated.
Similarly to FGF23, serum sclerostin levels could be considered inappropriately high in ADPKD. Indeed, in agreement with other investigators (35), we demonstrated a direct relationship between serum phosphate and circulating sclerostin levels. We acknowledge that this hypothesis is highly speculative and that further investigations are required to explore the role of other players involved in the Wnt/b-catenin signaling pathway.
Clinical studies have shown changing sclerostin exposure during puberty, depending on sex (38) . Because 25% to 50% of the adult bone mass is accrued during puberty, the growing skeleton might be particularly vulnerable to overactivity of sclerostin. Whether sclerostin overactivity in ADPKD, if confirmed, is clinically relevant, remains to be investigated.
Some strengths and limitations of this study need consideration. An important strength is that we prospectively analyzed a large and very well-characterized pediatric ADPKD cohort. The sample size, however, is still too small to account for important covariables such as puberty stage and growth.
To conclude, we demonstrate that ADPKD children with preserved renal function display significantly lower levels of serum phosphate, with renal phosphate wasting in one-quarter of the population. Moreover, bone turnover may be suppressed from early-stage ADPKD. Even though the levels of FGF23 and sclerostin were not different from HC, they were maladaptive considering the low serum phosphate levels.
